Lactobacillus reuteri DSM 17938 feeding of healthy newborn mice regulates immune responses while modulating gut microbiota and boosting beneficial metabolites.

doi:10.1152/ajpgi.00107.2019

Paper

Lactobacillus reuteri DSM 17938 feeding of healthy newborn mice regulates immune responses while modulating gut microbiota and boosting beneficial metabolites.

Published Dec 1, 2019 · Yuying Liu, X. Tian, Baokun He

American journal of physiology. Gastrointestinal and liver physiology

UNKNOWN SJR score

65

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Early administration of Lactobacillus reuteri DSM 17938 (LR) prevents necrotizing enterocolitis and inhibits Treg-deficiency-associated autoimmunity in mice. In humans, LR reduces crying time in breastfed infants with colic, modifies severity in infants with acute diarrheal illnesses, and improves pain in children with functional bowel disorders. In healthy breastfed newborns with evolving microbial colonization, it is unclear if early administration of LR can modulate gut microbiota and their metabolites in such a way as to promote homeostasis. We gavaged LR (107 CFU/day, daily) to C57BL/6J mice at age of day 8 for 2 weeks. Both male and female mice were investigated in these experiments. We found that feeding LR did not affect clinical phenotype or inflammatory biomarkers in plasma and stool, but LR increased the proportion of Foxp3+ regulatory T cells (Tregs) in the intestine. LR also increased bacterial diversity and the relative abundance of p_Firmicutes, f_Lachnospiraceae, f_Ruminococcaceae, and genera Clostridium and Candidatus arthromitus, while decreasing the relative abundance of p_Bacteriodetes, f_Bacteroidaceae, f_Verrucomicrobiaceae, and genera Bacteroides, Ruminococcus, Akkermansia and Sutterella. Finally, LR exerted a major impact on the plasma metabolome, upregulating amino acid metabolites formed via the urea, tricarboxylic acid, and methionine cycles and increasing tryptophan metabolism. In conclusion, early oral administration of LR to healthy breastfed mice led to microbial and metabolic changes which could be beneficial to general health.

Non-RCT

Animal Study

Study Snapshot

Early oral administration of Lactobacillus reuteri DSM 17938 to healthy newborn mice led to beneficial gut microbiota and metabolic changes, potentially promoting general health.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Lactobacillus reuteri DSM 17938 feeding of healthy newborn mice regulates immune responses while modulating gut microbiota and boosting beneficial metabolites.

Sign up to use Study Snapshot

References

The potential therapeutic role of Lactobacillus reuteri for treatment of inflammatory bowel disease.

Lactobacillus reuteri may have potential as a new therapeutic agent for treating inflammatory bowel disease by restoring intestinal homeostasis and reducing inflammation through multiple mechanisms.

Dysregulated Mucosal Immunity and Associated Pathogeneses in Preterm Neonates

Preterm neonates are more vulnerable to infections due to delayed immune maturation, which contributes to unique diseases like necrotizing enterocolitis and lung and brain injury.

The Control of Intestinal Inflammation: A Major Objective in the Research of Probiotic Strains as Alternatives to Antibiotic Growth Promoters in Poultry

Probiotics show promise in reducing gut inflammation and improving productivity in poultry, but specific strains and pathways need further research to optimize productivity and animal health.

Mucosal healing and bacterial composition in response to enteral nutrition versus steroid based induction therapy - a randomized prospective clinical trial in children with Crohn's disease.

Enteral nutrition (EEN) is as effective as corticosteroids in achieving clinical remission in children with Crohn's disease, but EEN-induced remission leads to a higher rate of mucosal healing and a different gut microbiota compositional shift compared to steroid-

Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study

Gut microbiota in children with type 1 diabetes and MODY2 differs in composition and function compared to healthy subjects and a model of nonautoimmune diabetes.

Citations

Evaluating the Efficacy of Secondary Metabolites in Antibiotic-Induced Dysbiosis: A Narrative Review of Preclinical Studies

Plant-derived secondary metabolites show promise in managing antibiotic-induced dysbiosis by restoring gut microbial balance, reducing inflammation, and improving gut barrier function in preclinical studies.

Digging deeper into necrotizing enterocolitis: bridging clinical, microbial, and molecular perspectives.

Probiotics and novel biologics show potential in modulating necrotizing enterocolitis-associated inflammatory pathways, potentially improving therapeutic interventions for preterm infants.

Importance of Lactobacilli for Human Health

Lactobacilli play a crucial role in human health by shaping and developing the immune system, with potential benefits from their interactions with mucosal and immune cells.

Limosilactobacillus reuteri ameliorates maternal separation stress in newborn mice and alters subsequent adult behaviour.

DSM 17938 improves growth, cognitive function, and reduces anxiety in newborn mice exposed to maternal separation stress, with benefits persisting into adulthood.

The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT

Probiotics Limosilactobacillus reuteri ATCC PTA 6475 and L. reuteri DSM 17938 showed potential anti-inflammatory and symptom-improving properties in IBS-D patients, but did not significantly affect gut barrier function.